| Download a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Includes 3 quarterly updated outlook reports!
Bangladesh is one of the ten most populous countries in the world. It is also
one of the poorest. Access to even the most basic of healthcare provision
remains sub-standard, despite the ongoing efforts of the government, aided by
considerable international assistance. Adequate secondary or tertiary care is
beyond the reach of all but a very few people. Government hospitals are often
little more than clinics, and suffer from severe shortages of trained staff.
There is a growing private hospital sector, largely based in Dhaka, which
caters for the well-off. It is in the private sector where the most advanced
services are located, and where almost all pharmaceutical demand is found.
The nation is experiencing political uncertainty. A military-backed interim
government under Fakrhuddin Ahmed, in power since October 2006 has been forced
to declare a state of emergency. In April 2007, two prominent political
figures, Khaleda Zia and Sheikh Hasina were exiled and dozens have been killed
in protests on the streets of Dhaka. Elections are expected to take place by
the end of 2008, in the meantime the army is considering initiating martial
law.
Given the country's lack of spending power, the pharmaceutical market, at
US$650 million, remains tiny in comparison with the size of the population.
Pharmaceutical spending is amongst the lowest in the world in per capita
terms. Steadily improving economic performance, combined with a general
determination to boost the quality of healthcare, should lead to steady, if
unspectacular, market growth. With a ruling party in power holding a sizeable
majority, it is hoped that legislation and initiatives regarding health and
welfare issues can be implemented with greater ease and efficacy. An increase
in investment in Bangladesh by multinational pharmaceutical manufacturers is
also anticipated to stimulate the sector. The revised National Drug Policy was
introduced in 2005 with the hope of attracting foreign multinational
investment and revitalising the health sector in the long term. In addition
the continually improving performance of Beximco, the leading domestic
manufacturer, offers encouraging signs for the future. The market is dominated
by cheap, locally produced generic drugs used for the treatment or prevention
of basic illnesses and conditions.
TABLE OF CONTENTS
BANGLADESH: BACKGROUND DATA
- GEOGRAPHY
- POLITICAL OVERVIEW
- ECONOMIC OVERVIEW
- POPULATION
- Population Forecasts by Source, 2000-2006 (millions)
- DEMOGRAPHIC INDICATORS
- Principal Demographic Indicators, 1994-2004
- MORTALITY
- MORBIDITY
- Estimated Prevalence of Selected Illnesses, 1997
- Reported Communicable Diseases, 1995-1998
CHARTS
- Population by Age Group, 2004 (%)
BANGLADESH: HEALTHCARE SYSTEM
- ORGANISATION & ADMINISTRATION
- HEALTH EXPENDITURE
- Budgeted Government Health Expenditure, 1997/98-2000/01 (Tk millions)
- Public Health Expenditure by Type, 1993/94-1996/97 (Tk millions)
- HOSPITAL SERVICES
- Hospitals by Type, 1996-2000
- Hospitals by Region (Division), 1996/97
- Beds by Type, 1996-2000
- Public Beds by Region (Division), 1996/7
- Hospital Beds, 1992-2000
- Private Hospitals by District, 1996/97
- AMBULATORY CARE
- Public Primary Care Facilities, 1994-2004
- MEDICAL PERSONNEL
- Medical Personnel, 1992-2004
CHARTS
- Public Health Expenditure 1988/89-2000/01 (Tk millions)
BANGLADESH: ACCESSING THE PHARMACEUTICAL MARKET
- INTRODUCTION
- REGULATORY ENVIRONMENT
- National Drug Policy
- Traditional Medicine
- Patent Protection & Intellectual Property Rights
- DISTRIBUTION CHANNELS
- Distributors
- TRADE FAIRS
- DOMESTIC PRODUCTION
- Domestic Pharmaceutical Production, 1989-1999
- Licensed Pharmaceutical Businesses by Categories, 1996-2000
- Beximco
- Novartis (Bangladesh) Limited
- BAPI Members, 2007
- DIRECTORY
- Organisations
- Trade Associations
CHARTS
- Domestic Pharmaceutical Production, 1989-1999 (US$ millions)
|
